Select Bibliography

Filter by any of these (after searching):

Lin, T. S.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 6 items

Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

Blum, K. A. , Jung, S.-H. , Johnson, J. L. , Lin, T. S. , Hsi, E. D. ... - - Ann Oncol - 2010

Manuscript - Primary - Primary - Lymphoma - CALGB-50502

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

Jones, J. A. , Ruppert, A. S. , Zhao, W. , Lin, T. S. , Rai, K. ... - - Leuk. Lymphoma - 2013

Manuscript - Secondary-not-in-original - Comprehensive - Leukemia - CALGB-19901 , CALGB-10101

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials

Jones, J. A. , Stark, A. , Zhao, W. , Lin, T. S. , Rai, K. R. ... - ASH - Blood - 2011

Abstract - Secondary-not-in-original - Comprehensive - Leukemia - CALGB-10101 , CALGB-19901

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101

Lin, T. S. , Donohue, K. A. , Byrd, J. C. , Lucas, M. S. , Hoke, E. ... - ASH - Blood - 2009

Abstract - Primary - Primary - Leukemia - CALGB-10101

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101

Lin, T. S. , Donohue, K. A. , Lucas, M. S. , Byrd, J. C. ... - - Blood - 2007

Abstract - Primary - Preliminary - Leukemia - CALGB-10101

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Woyach, J. A. , Ruppert, A. S. , Peterson, B. , Rai, K. R. ... - ASH - Blood - 2011

Abstract - Secondary-not-in-original - Meta-Analysis - Leukemia - C9011 , CALGB-10101 , CALGB-9712